Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

613 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.
Bachmayer S, Fastner G, Vaszi A, Iglseder W, Kopp P, Holzinger J, Dinnewitzer A, Rinnerthaler G, Gampenrieder SP, Emmanuel K, Greil R, Sedlmayer F, Zehentmayr F. Bachmayer S, et al. Among authors: kopp p. Strahlenther Onkol. 2018 Jul;194(7):627-637. doi: 10.1007/s00066-018-1281-7. Epub 2018 Mar 1. Strahlenther Onkol. 2018. PMID: 29497791 Free PMC article.
DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K, Zehentmayr F, Deutschmann H, Dagn K, Exeli AK, Kopp P, Porsch P, Maurer B, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: kopp p. Strahlenther Onkol. 2017 Apr;193(4):315-323. doi: 10.1007/s00066-016-1095-4. Epub 2017 Jan 23. Strahlenther Onkol. 2017. PMID: 28116446 Free PMC article. Clinical Trial.
NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study.
Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: kopp p. Strahlenther Onkol. 2007 Dec;183 Spec No 2:38-40. doi: 10.1007/s00066-007-2015-4. Strahlenther Onkol. 2007. PMID: 18167008 No abstract available.
DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K, Deutschmann H, Dagn K, Kopp P, Zehentmayr F, Lamprecht B, Porsch P, Wegleitner B, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: kopp p. Radiat Oncol. 2013 Mar 5;8:49. doi: 10.1186/1748-717X-8-49. Radiat Oncol. 2013. PMID: 23497555 Free PMC article.
IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.
Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, Greil R, Fischer T, Deutschmann H, Sedlmayer F. Fastner G, et al. Among authors: kopp p. Int J Cancer. 2015 Mar 1;136(5):1193-201. doi: 10.1002/ijc.29064. Epub 2014 Jul 10. Int J Cancer. 2015. PMID: 24995409
613 results